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INTRODUCTION 
The incidence of new-onset postoperative atrial fibrillation 
(POAF) ranges from 25 to 40% after coronary artery bypass 
graft (CABG) surgery and up to 62% after a combined CABG 
and valve procedure.1-3 POAF has been shown to be associat-
ed with an increased risk of postoperative stroke and an in-
creased length of hospital stay.4 As the demographic profile of 
patients undergoing CABG shifts toward adults of older age, 
the incidence of POAF will increase, because the frequency of 
this complication sharply increases with age.5 Although POAF 
has been commonly regarded as a benign, transient, and self-
limited complication after cardiac surgery, it has been found 
to be associated with perioperative myocardial infarction, re-
nal failure, cognitive dysfunction, infective complications, 
higher readmission rate, and increasing medical costs.5-8 It has 
been demonstrated that long-term mortality is increased in 
patients with an episode of POAF because of an increased risk 
of cardiovascular death.7,9 Recently, we found that POAF is in-
dependently associated with long-term (>1 year) newly devel-
oped atrial fibrillation (LTAF) and mortality.10 However, the 
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Purpose: New-onset postoperative atrial fibrillation (POAF) is associated with poor short- and long-term outcomes after isolated 
coronary artery bypass graft (CABG) surgery. This study evaluated gender differences in the long-term clinical implications of POAF.  
Materials and Methods: After propensity score matching, a gender-based comparison of long-term (>1 year) newly developed 
atrial fibrillation (LTAF) and mortality between 1664 (480 females) consecutive patients with (POAF) and without POAF (no-
POAF) who had undergone CABG was performed. 
Results: During a follow-up of 49±28 months, cumulative survival free of LTAF was lower in the POAF group than in the no-POAF 
group for both males (92.1% vs. 98.2%, p<0.001) and females (84.1% vs. 98.0%, p<0.001). However, female patients with POAF 
more frequently developed LTAF than male POAF patients (13.9 % vs. 6.9%, p=0.049). In multivariate analysis, POAF was a signifi-
cant predictor of LTAF among males [hazard ratio (HR) 4.91; 95% confidence interval (CI) 1.22−19.79, p=0.031] and females (HR 
16.50; 95% CI 4.79−56.78; p<0.001). POAF was a predictor of long-term mortality among females (adjusted HR 3.96; 95% CI 
1.13−13.87, p=0.033), but not among males.
Conclusion: Although POAF was related to LTAF in both genders, cumulative survival free of LTAF was poorer among females 
than among males. Additionally, a significant correlation with long-term mortality after CABG was observed among female pa-
tients with POAF.
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gender differences in the long-term prognosis and the effect 
of POAF has not been fully elucidated. Therefore, we aimed to 
investigate gender differences in the long-term prognosis and 
the effect of POAF.
MATERIALS AND METHODS
Patients
The study protocol was approved by the Institutional Review 
Board of Severance Cardiovascular Hospital, Seoul, Korea and 
complied with the Declaration of Helsinki. We used Interna-
tional Statistical Classification of Disease and Related Health 
Problems, 10th revision, codes to identify 1810 consecutive 
adult patients who underwent an isolated CABG at the Sever-
ance Cardiovascular Hospital, Yonsei University Health Sys-
tem, between January 2005 and December 2011. Patients with 
a history of atrial fibrillation (AF) (n=94) or emergency surgery 
(n=38) and those who had insufficient medical records (n=8) 
were excluded. Additionally, patients who died within 10 days 
after surgery (n=6) were excluded. Finally, we enrolled 1664 
patients who were divided into two groups based on their gen-
der (females, n=480 and males, n=1184) (Fig. 1).
We obtained detailed information regarding patient demo-
graphics, preoperative risk factors, operative details, postop-
erative hospital courses, and morbidity and mortality outcomes 
from the hospital database and through telephone calls. Renal 
dysfunction was defined as a serum creatinine level of >1.5 
mg/dL for at least 3 months and/or the presence of kidney 
damage (persistent microalbuminuria, proteinuria, or hema-
turia after the exclusion of urological causes or structural ab-
normalities detected on kidney imaging tests). Renal failure 
was defined as a serum creatinine elevation of >three times the 
baseline or a serum creatinine level of >2.0 mg/dL. Obesity 
was defined as a body mass index ≥30 kg/m2. Significant coro-
nary artery disease was defined as visualized luminal narrow-
ing of each vessel of >50%. Hypercholesterolemia was defined 
as patients having abnormal preoperative lipid profiles ac-
cording to the American Heart Association Guidelines or be-
ing previously diagnosed and treated by physicians. Before the 
surgery, the volume of the left atrium (LA) was measured us-
ing echocardiography, through the biplane Simpson’s method; 
the LA volume index was calculated as the LA volume/body 
surface area (mL/m2). Diastolic dysfunction was defined as an 
E to e’ ratio of >15 on echocardiography.
Management and follow-up
POAF was defined as newly developed AF documented using 
electrocardiography (ECG) or continuous monitoring during 
the first 10 days after surgery. To restore sinus rhythm in most 
patients within 24 h after the onset of POAF, electrolyte re-
placement, antiarrhythmic drugs (AADs), or electrical cardio-
version was applied. Patients with AF who were discharged to 
their home were maintained on warfarin (in the absence of 
any contraindications) and usually referred for cardioversion 
after 3−6 weeks. In the absence of any evidence of AF recur-
rence, AADs were stopped, and this decision was left to the 
discretion of the treating physician. All patients were followed 
up with a clinical examination and ECG at 2 weeks, 1 month, 3 
months, and every 6 months thereafter. In case of symptom 
recurrence between follow-up visits, patients were evaluated 
with a clinical examination, ECG, and Holter monitoring. 
Outcomes, including mortality, stroke, renal failure, and AF, 
were evaluated in the follow-up period. Recurrent AF was de-
fined as any recurrent AF documented in the patients’ medical 
and ECG records. In this study, AF that occurred within 1 year 
after surgery was not included under LTAF (Supplementary Ta-
ble 1, only online). Additionally, mortality was defined as 
death from any cause that occurred at any time after hospital 
discharge. There were no missing data on preoperative patient 
characteristics in this study. Long-term follow-up (>1 year) was 
achieved in 92.3% (1536/1664) of the patients.
Statistical analysis
All continuous data are expressed as a mean±standard devia-
tion (SD), and categorical data are reported as an absolute num-
ber or percentage. Student’s unpaired t-test or Welch’s t-test 
was adopted based on variance tests for the distribution. Fish-
er’s exact test or Pearson’s chi-squared test with Yates’ conti-
nuity correction (expected frequency >5) was used to compare 
groups of categorical variables. All calculated p-values were 
two-sided, and p-values of <0.05 were considered statistically 
CABG (n=1810)
• History of AF (n=94)
• Emergency operations (n=38)
• No medical data (n=8)
• Death <10 days after the CABG (n=6)
Fig. 1. Flow diagram and follow-up for new-onset POAF, LTAF, and mor-
tality. CABG, coronary artery bypass graft; AF, atrial fibrillation; POAF, 
postoperative atrial fibrillation; LTAF, long-term (>1 year) newly devel-
oped atrial fibrillation.
1:1 Propensity score matching
Male (n=393)
POAF
(n=102)
LTAF (n=7)
Death (n=14)
POAF
(n=79)
LTAF (n=11)
Death (n=9)
 No POAF
(n=291)
LTAF (n=5)
Death (n=15)
 No POAF
(n=314)
LTAF (n=6)
Death (n=10)
Female (n=393)
Enrolled patients (n=1664)
(Male:Female=1184:480)
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significant. Statistical analyzes were performed using R Statis-
tical Software, version 3.0.1 (Foundation for Statistical Comput-
ing, Vienna, Austria).
The clinical characteristic variables were compared be-
tween males and females before matching, which showed sig-
nificant differences. To reduce the effect of selection bias and 
heterogeneity of the gender subgroup in this retrospective co-
hort study, estimated propensity scores were used to match the 
patients according to gender, using R Statistical Software with 
the MatchIt package.11 Propensity scores were computed for 
each of the patients using a logistic regression model compris-
ing all 20 variables of baseline characteristics that could have 
been confounders of AF, such as age, stroke, chronic obstruc-
tive pulmonary disease (COPD), renal dysfunction, diabetes, 
hypercholesterolemia, hypertension, congestive heart failure, 
peripheral artery occlusive disease, history of percutaneous 
coronary intervention, recent myocardial infarction, three-
vessel disease, left main disease, left ventricular ejection frac-
tion, E/e’ ratio, LA volume index, and preoperative medica-
tions. A nearest-neighbor matching algorithm was used to 
match participants, with matches occurring if the difference 
in the logits of the propensity scores was >0.2 times the SD of 
the scores. The propensity score model was well calibrated 
(Hosmer-Lemeshow goodness-of-fit test, p=0.3562), with good 
discrimination (Harrell’s c index=0.76). Based on the propensi-
ty scores, 393 male patients were matched to 393 female pa-
tients (Fig. 1).
A Kaplan-Meier estimate of survival was obtained to investi-
gate the differences in mortality and survival free from AF be-
tween the male and female groups. Cox proportional hazard 
models were used to test the significance of POAF in survival 
free from LTAF and long-term mortality. We selected the most 
appropriate model according to the Akaike Information Crite-
ria and principal of parsimony. The assessment of model ade-
quacy was confirmed using scaled Schoenfeld residuals for 
each variable interaction with time (log). The hazard ratios 
(HRs), 95% confidence intervals (CIs), and p-values were also 
reported. In this study, the estimated AF incidence differences 
between the study groups might have been biased because pa-
tients who died during the follow-up might not have survived 
long enough to develop AF. Therefore, we calculated the HR of 
competing risk regression using death as a competing event. 
RESULTS
Gender differences in pre- and postoperative 
characteristics, including POAF
Among 1664 enrolled patients, 480 (28.8%) were female, and 
>90% of the patients had undergone off-pump surgery in this 
Table 1. Preoperative Characteristics and Operation Data Stratified by Gender 
Variable
Overall series Propensity score-matched pairs
Male 
(n=1184)
Female 
(n=480)
p value
Male 
(n=393)
Female 
(n=393)
p value
Age (yr, mean±SD) 63±9 66±7 <0.001 66±8 66±7 0.731
Stroke, n (%) 28 (2.4)   7 (1.5) 0.328   9 (2.3)   7 (1.8) 0.801
Chronic obstructive pulmonary disease, n (%) 30 (2.5)   8 (1.7) 0.373   7 (1.8)   8 (2.0) 1.000
Renal dysfunction, n (%) 122 (10.3) 26 (5.4) 0.002 27 (6.9) 21 (5.3) 0.456
Diabetes mellitus, n (%) 461 (38.9) 231 (48.1) 0.001 173 (44.0) 182 (46.3) 0.566
Hypercholesterolemia, n (%) 686 (57.9) 252 (52.5) 0.049 202 (51.4) 214 (54.5) 0.432
Hypertension, n (%) 774 (65.4) 363 (75.6) <0.001 285 (72.5) 290 (73.8) 0.747
Congestive heart failure, n (%) 68 (5.7) 33 (6.9) 0.446 31 (7.9) 25 (6.4) 0.488
Peripheral vascular disease, n (%) 92 (7.8) 21 (4.4) 0.017 17 (4.3) 18 (4.6) 1.000
Recent myocardial infarction, n (%) 168 (14.2)   58 (12.1) 0.291   55 (14.0)   42 (10.7) 0.193
Three-vessel disease, n (%) 792 (66.9) 320 (66.7) 0.975 271 (69.0) 261 (66.4) 0.492
Left main disease, n (%) 271 (22.9)   87 (18.1) 0.038   69 (17.6)   70 (17.8) 1.000
LV ejection fraction (%)   55.0±14.2   59.6±14.0 <0.001   58.4±14.0   59.1±14.0 0.490
E/e’ 13.0±5.5 16.2±7.1 <0.001 14.9±6.5 14.7±5.3 0.624
LA volume index (mL/m2) 26.9±9.4 29.7±9.9 <0.001   30.0±10.5 28.4±9.2 0.382
Medication, n (%)
Statin 460 (38.9) 194 (40.4) 0.591 155 (39.4) 159 (40.5) 0.827
Beta-blocker 583 (49.2) 256 (53.3) 0.145 196 (49.9) 198 (50.4) 0.943
ACEI+ARB 400 (33.8) 184 (38.3) 0.088 143 (36.4) 142 (36.1) 1.000
Calcium antagonist 433 (36.6) 192 (40.0) 0.210 152 (38.7) 155 (39.4) 0.884
POAF 306 (25.8) 107 (22.3) 0.145 102 (26.0)   79 (20.1) 0.062
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blocker; LA, left atrial; LV, left ventricular; POAF, postoperative atrial fibrillation; SD, 
standard deviation. 
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study. The preoperative characteristics and operative data of 
the male and female groups are presented in Table 1. Com-
pared with the male patients, the female patients were older 
(63±9 years vs. 66±7 years, p<0.001) and more frequently had 
diabetes (38.9% vs. 48.1%, p=0.001), hypertension (65.4% vs. 
75.6%, p<0.001), a higher E/e’ ratio (13.0±5.5 vs. 16.2±7.1, p< 
0.001), and a larger LA volume index (26.9±9.4 mL/m2 vs. 
29.7±9.9 mL/m2, p<0.001). However, renal dysfunction (10.3% 
vs. 5.4%, p=0.002), peripheral vascular disease (7.8% vs. 4.4%, 
p=0.017), and hypercholesterolemia (57.9% vs. 52.5%, p=0.049) 
were more common among the male patients. Except for POAF, 
no gender differences were found in the postoperative data of 
both overall and propensity score-matched pairs (Supplemen-
tary Table 1, only online). The incidence of POAF exhibited no 
statistical differences between males and females among the 
overall patients. However, after propensity score matching, the 
male group exhibited a trend of higher POAF incidence (26.0% 
vs. 20.1%, p=0.062), compared with the female group. 
Gender differences in the preoperative characteristics 
stratified by POAF 
Table 2 shows the preoperative characteristics and operative 
data after a propensity score matching stratified by POAF. 
Among both genders, the POAF group was older and more fre-
quently had a higher E/e’ ratio and a larger LA volume index 
(all p<0.050).
Gender differences in the perioperative data stratified 
by POAF
In the female patients, POAF was related to increased hospi-
talization duration (16±12 days vs. 28±51 days, p=0.049). Among 
the male patients, postoperative complications, including pneu-
monia (0.3% vs. 6.9%, p<0.001) and stroke (1.0% vs. 4.9%, p= 
0.031), were more frequently observed in the POAF group than 
in the no-POAF group (Table 3). Among both genders, digoxin 
and amiodarone were more commonly used in the POAF group 
than in the no-POAF group (all p<0.050).
Gender differences in the incidence and risk factors 
for LTAF
During follow-up of 49±28 months, the POAF group exhibited 
higher overall AF (2.2% vs. 21.1%, p<0.001) and LTAF (1.8% vs. 
9.2%, p<0.001) rates than the no-POAF group in all patients. 
After propensity score matching, the POAF group had a high-
er incidence of overall AF and LTAF than the no-POAF group 
among both genders (all p<0.001). Fig. 2 shows the Kaplan-
Meier survival curves for LTAF, according to the presence of 
POAF in the overall (Fig. 2A) and propensity score-matched 
patients (Fig. 2B). Regarding the propensity score-matched 
pairs, the POAF group had a lower cumulative survival free of 
Table 2. Preoperative Characteristics after Propensity Score Matching Stratified by POAF
Variable
Males (n=393) Females (n=393)
No-POAF
(n=291)
POAF
(n=102)
p value
No-POAF
(n=314)
POAF
(n=79)
p value
Age (yr, mean±SD) 65±8 69±7 <0.001 65±7 68±7 0.001
Stroke, n (%)   8 (2.7)   1 (1.0) 0.520   6 (1.9)   1 (1.3) 1.000
Chronic obstructive pulmonary disease, n (%)   2 (0.7)   5 (4.9) 0.020   4 (1.3)   4 (5.1) 0.055
Renal dysfunction, n (%) 17 (5.8) 10 (9.8) 0.257 18 (5.7)   3 (3.8) 0.686
Diabetes mellitus, n (%) 125 (43.0)   48 (47.1) 0.547 140 (44.6)    42 (53.2) 0.215
Hypercholesterolemia, n (%) 161 (55.3)   41 (40.2) 0.012 176 (56.1) 38 (21) 0.254
Hypertension, n (%) 211 (72.5)   74 (72.5) 1.000 230 (73.2)   60 (75.9) 0.730
Congestive heart failure, n (%) 25 (8.6)   6 (5.9) 0.509 20 (6.4)   5 (6.3) 1.000
Peripheral vascular disease, n (%) 11 (3.8)   6 (5.9) 0.538 13 (4.1)   5 (6.3) 0.377
History of PCI, n (%)   42 (14.4)   17 (16.7) 0.702   41 (13.1)   12 (15.2) 0.755
Recent myocardial infarction, n (%)   34 (11.7)   21 (20.6) 0.039 29 (9.2)   13 (16.5) 0.098
Three-vessel disease, n (%) 195 (67.0)   76 (74.5) 0.199 207 (65.9)   54 (68.4) 0.783
Left main disease, n (%)   51 (17.5)   18 (17.6) 1.000   53 (16.9)   17 (21.5) 0.424
LV ejection fraction (%)   59.0±13.6   56.6±14.9 0.126   59.3±13.6   58.0±15.6 0.447
E/e’ 14.5±6.1 16.2±7.5 0.047 14.5±5.4 15.8±5.0 0.049
LA volume index (mL/m2) 27.3±9.5   33.8±11.7 <0.001 27.3±8.5   32.6±10.5 <0.001
Medication, n (%)
Statin 117 (40.2)   38 (37.3) 0.684 121 (38.5)   39 (48.1) 0.156
Beta-blocker 138 (47.4)   58 (56.9) 0.127 148 (47.1)   50 (63.3) 0.015
ACEI+ARB 104 (35.7)   39 (38.2) 0.740 104 (33.1)   38 (48.1) 0.019
Calcium antagonist 106 (36.4)   46 (45.1) 0.153 124 (39.5)   31 (39.2) 1.000
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blocker; LA, left atrial; LV, left ventricular; PCI, percutaneous coronary intervention; 
POAF, postoperative atrial fibrillation; SD, standard deviation. 
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LTAF than the no-POAF group among male (92.1% vs. 98.2%, 
p<0.001) and female (84.1% vs. 98.0%, p<0.001) genders. Fur-
thermore, female patients with POAF more frequently had 
LTAF than did male patients with POAF, according to Kaplan-
Meier survival analysis (6.9% vs. 13.9 %, p=0.049) (Fig. 2B). 
Table 4 presents the multivariate adjusted HRs of LTAF as-
sociated with POAF. In the competing risk model, patients 
with POAF had a higher risk of LTAF among both male (ad-
justed HR 4.91; 95% CI 1.22−19.79; p=0.031) and female (ad-
justed HR 16.50; 95% CI 4.79−56.78; p<0.001) genders. Addi-
tionally, LTAF was associated with COPD in both male (adjusted 
HR 17.68; 95% CI 1.39−224.58; p=0.032) and female patients 
(adjusted HR 12.71; 95% CI 1.81−89.06; p=0.011). Furthermore, 
congestive heart failure (adjusted HR 16.08; 95% CI 3.17− 
81.56; p<0.001) and renal dysfunction (adjusted HR 14.16; 95% 
CI 3.62−55.36; p<0.001) were significant predictors of LTAF 
among females, and postoperative beta-blocker usage (ad-
justed HR 0.05; 95% CI 0.01−0.20; p<0.001) was a significant 
predictor of LTAF among males.
Gender differences in the incidence and risk factors 
for long-term (>1 year) mortality
During follow-up, the POAF group had a higher overall mor-
tality (3.5% vs. 10.7%, p<0.001) than the no-POAF group in all 
the patients. Fig. 3 shows the Kaplan-Meier survival curves for 
long-term mortality, according to the presence of POAF in the 
overall (Fig. 3A) and propensity score-matched (Fig. 3B) pa-
tients. After propensity score matching, the POAF group had a 
lower cumulative survival free of long-term mortality than the 
no-POAF group among both genders (all p<0.05). Unlike pa-
tients with LTAF, there were no significant differences in long-
term mortality between male and female patients with POAF 
(13.7% vs. 11.4%, p=0.922), according to the Kaplan-Meier sur-
vival analysis. 
Table 4 presents the multivariate adjusted HRs for long-term 
mortality associated with POAF. In the Cox proportional haz-
ards model, POAF was a risk factor for long-term mortality 
among females (adjusted HR 3.96; 95% CI 1.13−13.87; p= 
0.033) but not among males. Diabetes was a significant risk 
factor for long-term mortality among both male (adjusted HR 
3.04; 95% CI 1.05−8.79; p=0.043) and female (adjusted HR 4.14; 
Table 3. Operative Data after Propensity Score Matching Stratified by POAF
Variable
Males (n=393) Females (n=393)
No-POAF
(n=291)
POAF
(n=102)
p value
No-POAF
(n=314)
POAF
(n=79)
p value
On-pump procedure, n (%)  19 (6.5)   7 (6.9) 1.000 14 (4.5)      8 (10.1) 0.059
Total pump time (min, mean±SD) 100±31 87±36 0.373 112±29 95±36 0.223
Aortic cross-clamp time (min, mean±SD)   59±36 53±43 0.707   80±40 58±52 0.280
Number of distal anastomoses (mean±SD)   3.2±0.8 3.1±0.8 0.475   3.1±0.8 3.1±0.7 0.741
Internal mammary artery graft used, n (%)  288 (99.0) 100 (98.0) 0.608 308 (98.1)    78 (98.7) 1.000
Radial artery graft used, n (%)  202 (69.4)   66 (64.7) 0.450 214 (68.2)    56 (70.9) 0.739
Perioperative pacing, n (%)    59 (20.3)   18 (17.6) 0.667   61 (19.4)    14 (17.7) 0.854
Postoperative medication, n (%)
Beta-blocker  276 (94.8)   96 (94.1)  0.980 298 (94.9)    76 (96.2) 0.776
Digoxin    6 (2.1)   26 (25.5) <0.001   7 (2.2)    25 (31.6) <0.001
Amiodarone    2 (0.7) 10 (9.8) <0.001   3 (1.0)    11 (13.9) <0.001
Calcium antagonist  258 (88.7)   86 (84.3) 0.332 273 (86.9)    65 (82.3) 0.375
Tambocor 0 (0)   2 (2.0) 0.067 0 (0) 0 (0)
Hospitalization duration (days)   16±17 19±12 0.206   16±12 28±51 0.049
Discharge medication, n (%)
Beta-blocker  283 (97.3)   97 (95.1) 0.335 300 (95.5)    75 (94.9) 0.767
Digoxin    4 (1.4) 18 (5.7) <0.001   2 (0.6)    15 (19.0) <0.001
Amiodarone    1 (0.3)   6 (5.9) 0.002   1 (0.3)    5 (6.3) <0.001
Calcium antagonist  229 (78.7)   75 (73.5) 0.350 261 (83.1)    62 (78.5) 0.424
Tambocor 0 (0)   1 (1.0) 0.259 0 (0) 0 (0)
Postoperative complications, n (%)
Pneumonia    1 (0.3)   7 (6.9) <0.001   5 (1.6)    3 (3.8) 0.204
Wound infection    4 (1.4)   1 (1.0) 1.000   6 (1.9)    3 (3.8) 0.393
Gastrointestinal complication  11 (3.8)   3 (2.9) 1.000   7 (2.2)    2 (2.5) 1.000
Renal failure  18 (6.2)   13 (12.7) 0.057 17 (5.4)      8 (10.1) 0.202
Stroke    3 (1.0)   5 (4.9) 0.031   3 (1.0)    1 (1.3) 1.000
POAF, postoperative atrial fibrillation; SD, standard deviation. 
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95% CI 1.00−17.12; p=0.049) patients.
DISCUSSION
Major findings
The main finding of this study was that, although POAF was 
related to LTAF among both genders, cumulative survival free 
of LTAF was poorer in female patients than in male patients. 
Second, females with LTAF were related to multiple risk factors, 
including POAF, congestive heart failure, renal dysfunction, 
and COPD. Third, POAF was a determinant of long-term mor-
tality in female patients, but not in male patients. These differ-
ences suggest a need for more strict surveillance for AF among 
female patients.
Gender differences in POAF 
In both genders, POAF was a common risk factor, along with 
older age and COPD, and these patients more often presented 
with comorbidities, including a reduced left ventricular func-
tion and increased LA volume index. Although the incidence 
of POAF according to gender is controversial, several studies 
Table 4. Effect of Gender on LTAF or Mortality According to Significant Risk Factors in a Multivariate Regression Model
Risk factors
Male Female
Adjusted HR (95% CI) p value Adjusted HR (95% CI) p value
LTAF*
POAF   4.91 (1.22–19.79) 0.031 16.50 (4.79–56.78) <0.001
Congestive heart failure   1.97 (0.25–15.50) 0.516 16.08 (3.17–81.56) <0.001
Renal dysfunction   0.67 (0.02–16.05) 0.813 14.16 (3.62–55.36) <0.001
Chronic obstructive pulmonary disease   17.68 (1.39–224.58) 0.032 12.71 (1.81–89.06) 0.011
Postoperative beta-blocker usage 0.05 (0.01–0.20) <0.001     3.66 (0.07–192.20) 0.524
Long-term mortality†
POAF 2.26 (0.80–6.33) 0.117   3.96 (1.13–13.87) 0.033
Diabetes mellitus 3.04 (1.05–8.79) 0.043   4.14 (1.00–17.12) 0.049
POAF, postoperative atrial fibrillation; LTAF, long-term (>1 year) newly developed atrial fibrillation; HR, hazard ratio; CI, confidence interval.
*Adjusted for age, POAF, ejection fraction, left atrial volume index, on-pump surgery, chronic obstructive pulmonary disease, congestive heart failure, renal dys-
function, recent myocardial infarction, postoperative beta-blocker usage, and the propensity score, †Adjusted for age, POAF, ejection fraction, left atrial volume 
index, chronic obstructive pulmonary disease, hypercholesterolemia, diabetes mellitus, recent myocardial infarction, renal dysfunction, and the propensity score. 
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Fig. 2. Kaplan-Meier curves for survival free of LTAF according to the presence of POAF in the overall (A) and propensity score-matched patients (B). 
The left and right panels show the survival curves in the male and female patients according to POAF, respectively. The POAF group had a lower cu-
mulative survival free of LTAF than the no-POAF group among both the overall and propensity score-matched patients (all p<0.001). The female POAF 
group had a lower cumulative survival free of LTAF than the male POAF group among the propensity score-matched patients (p=0.049). LTAF, long-
term (>1 year) newly developed atrial fibrillation; POAF, postoperative atrial fibrillation; AF, atrial fibrillation.
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have reported that male patients more frequently have POAF 
after CABG.8,12 After propensity score matching, our results 
were also consistent with those of recent studies. However, 
women with AF generally had a lower quality of life and fre-
quently had more comorbidities than did men.13 Moreover, the 
significantly longer length of hospital stays among the female 
patients with POAF in our study could be similarly explained. 
Gender differences in the Role of POAF for LTAF 
Previously, new-onset POAF was commonly considered as 
being relatively easy to treat,14-16 and it rarely recurred after dis-
charge from the hospital.15 Other studies have reported that 
POAF is self-limiting, with a total prevalence of AF of 1−4% at 
1 year.15,17,18 On the contrary, recent studies have reported that 
patients with POAF are at an increased risk of developing over-
all AF19,20 and LTAF.10 However, the effects of gender differenc-
es in POAF on long-term follow-up are not fully elucidated. In 
this study, female patients had a poorer cumulative survival 
free of LTAF than did male patients.
POAF was a significant predictor of LTAF in both genders in 
our multivariate competing risk-adjusted model. However, 
the other covariates significantly differed according to gender. 
Postoperative beta-blocker use and COPD were significant 
predictors of LTAF in males, whereas congestive heart failure, 
COPD, and renal dysfunction were predictors in females. These 
results indicate that, for reducing LTAF, gender-specific risk 
assessment should be considered during pre- and periopera-
tive periods.
Gender differences in POAF as a risk factor for long-term 
mortality 
In general, AF is a well-established risk factor for mortality, 
stroke, and heart failure.21 Previous studies have reported that 
worse preoperative risk profiles in patients with POAF account-
ed for higher observed early and late mortality.14,20,22,23 In the 
present study, interestingly, the multivariate regression analy-
sis showed that POAF was a significant predictor of long-term 
mortality in females but not in males. Therefore, POAF in fe-
males should be treated as a severe complication with close fol-
low-up. There are some points to be considered regarding these 
results. First, the contributing factors for POAF might differ 
according to gender. Second, other confounding factors that 
were not addressed in this study, such as diet, exercise, and fam-
ily history, might also have affected the results. Among patients 
of both genders, diabetes was recognized as a risk factor for 
long-term mortality after CABG. This finding is consistent with 
previous studies.24,25 
Limitations of the study
First, we performed a risk adjustment in the overall patients 
by using the propensity score matching method. Therefore, a 
smaller number of patients were included in the analyses, and 
a decreased statistical power was inevitable. However, pro-
pensity score matching has been shown to provide unbiased 
and more reliable results.26 Second, the prevalence of AF and 
other long-term complications at follow-up might have been 
underestimated because of the retrospective study design. 
Third, the older age of patients in this study could lead to a 
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Fig. 3. Kaplan-Meier curves for survival free of long-term mortality according to the presence of POAF in the overall (A) and propensity score-
matched patients (B). The left and right panels show the survival curves in the male and female patients according to POAF, respectively. The POAF 
group had a lower cumulative survival free of long-term mortality than the no-POAF group among both the overall and propensity score-matched pa-
tients (all p<0.050). POAF, postoperative atrial fibrillation.
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bias, because old age affects the incidence of AF and absolute 
mortality.27 Fourth, despite the convincing findings, it is neces-
sary to interpret the results with caution, because POAF and 
other cardiovascular risk factors may not be completely inde-
pendent. Indeed, further large prospective cohort studies are 
necessary to determine the role of gender in long-term clini-
cal implications. Although our results could hardly be gener-
alized to all patients, it may reveal a relationship between POAF 
and long-term prognosis according to gender in off-pump 
CABG patients of older age.
Conclusions
After isolated CABG, POAF was a significant predictor of LTAF 
regardless of gender, and cumulative survival free of LTAF was 
poorer in female than in male patients. Furthermore, male and 
female patients had different risk predictors of LTAF. POAF was 
related to long-term mortality in only female patients. These 
gender differences in the clinical implications of POAF should 
be considered in careful postoperative surveillance aimed at 
reducing AF and its complications.
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